Icatibant is a bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. It is available as injection for subcutaneous use. MedsAcross supplies Icatibant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
FIRAZYR ® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. FIRAZYR is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Source: US FDA prescribing information
Icatibant is a competitive antagonist selective for the bradykinin B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production. Bradykinin is a vasodilator which is thought to be responsible for the characteristic HAE symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.
Source: US FDA prescribing information
30 mg injected subcutaneously in the abdominal area. If response is inadequate or symptoms recur, additional injections of 30 mg may be administered at intervals of at least 6 hours. Do not administer more than 3 injections in 24 hours. Patients may self-administer upon recognition of an HAE attack.
Source: US FDA prescribing information
None. None
Source: US FDA prescribing information
Laryngeal attacks: Following treatment of laryngeal attacks with FIRAZYR, advise patients to seek immediate medical attention. Laryngeal Attacks Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with FIRAZYR.
Source: US FDA prescribing information
The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials. Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.
Source: US FDA prescribing information
ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. Clinical trials to date have excluded subjects taking ACE inhibitors.
Source: US FDA prescribing information
Store between 2 - 25° C (36 - 77° F). Do not freeze. Store in carton until time of administration.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Icatibant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Icatibant 30 mg/3 mL injectionSubcutaneousGeneric name | — | US FDA | Available on request |
| Firazyr 30 mg/3 mL injectionSubcutaneous | Takeda Pharmaceuticals | US FDA | Available on request |
| Sajazir 30 mg/3 mL injectionSubcutaneous | Cycle Pharmaceuticals Ltd-Uk | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 3 presentations of Icatibant and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Icatibant, including Firazyr, Sajazir.
Yes. The US FDA first approved Icatibant on 25 August 2011, according to Drugs@FDA.
Yes. Icatibant has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Icatibant is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Icatibant is classified under ATC code B06AC02 (Icatibant).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.